Long-term use of antiretroviral therapy (ART) has reduced the morbidity and mortality due to HIV infection but has also led to dyslipidaemia, characterized by an increase in levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and varying effect on high-density lipoprotein cholesterol (HDL-C)[@ref1][@ref2][@ref3]. Alterations in these lipid levels may lead to an increased risk of cardiovascular disease (CVD), observed in both developed and resource-limited settings[@ref3][@ref4]. The changes seen in lipid levels appear to be related to both drug classes \[nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs)\] and specific agents \[zidovudine and nevirapine (NVP)\][@ref5][@ref6]. For example, NVP-based regimens show larger increases in HDL-C and relative decreases in TC:HDL-C ratio than efavirenz-containing regimens and thus could be associated with a lower atherogenic lipid profile[@ref7].

HDL, a lipoprotein responsible for the efflux and transport of blood cholesterol, plays an essential role in preventing atherosclerosis and cardiovascular events[@ref8]. A low level of HDL-C has been shown to be a risk factor for CVD in general population[@ref9]. Both HIV infection and ART can influence HDL-C levels, with NVP being associated with greater increase in HDL-C levels than efavirenz[@ref6][@ref10]. At the same time, strong genetic influence also exists on plasma HDL-C levels. Defects in the genes coding for cholesteryl ester transfer protein (*CETP*), lipoprotein lipase (*LPL*), apolipoprotein A1, lecithin cholesterol aceyltransferase (*LCAT*), etc. can result in large changes in HDL-C levels as does apolipoprotein C3 (*APOC3*) for cholesterol[@ref8][@ref11][@ref12]. *APOC3* promoter polymorphism is also associated with a greater likelihood of metabolic syndrome and dyslipidaemia, especially higher TG and lower HDL-C, among Indian population as well, after controlling for age, race and gender[@ref13][@ref14][@ref15]. Though functional defects of these genes are rare in the general population and mostly concern only small numbers of patients, premature truncation of the *LPL* protein (447 stop), polymorphism in *CETP* (rs4329913 and rs7202364) gene and *APOC3* promoter variant (C-482T and T-455C) have been shown to be relatively frequent and account for significant changes in lipid levels in various groups of population[@ref16][@ref17].

The high degree of risk for CVD in Indians is characterized by various combinations of either hypertriglyceridaemia with low HDL cholesterol or an increase in TC, LDL cholesterol and TC/HDL ratio[@ref18][@ref19]. Studies have shown significantly lower HDL-C among HIV-positive as compared to HIV-negative individuals (43 vs. 75%, *P* \<0.001), especially in treatment-naïve HIV-infected individuals with low CD4 cell counts[@ref20][@ref21][@ref22]. With immunological restoration following initiation of ART, HDL-C returns to normal range. However, we have previously reported that almost 25 per cent of HIV-infected adults have lower levels of HDL-C even after 12 months of NNRTI-based ART[@ref23]. This study was aimed to look at the factors and impact of certain baseline characteristics, CVD risk scores as well as polymorphisms in *APOC3*, *CETP* and *LPL* genes on lipid profile of HIV-infected adults after 12-15 months of NVP-based ART.

Material & Methods {#sec1-1}
==================

A cross-sectional study was conducted at the National Institute for Research in Tuberculosis, Chennai, India, between January 2013 and July 2014. HIV-infected adults of 18 yr and above, on an NVP-based ART regimen (dose of NVP: 200 mg twice a day along with two NRTI drugs) for the last 12-15 months, from ART centres in Government Hospital of Thoracic Medicine, Government General Hospital, Chennai, and Government Vellore Medical College and Hospital, Vellore, were approached for the participation in this study. Patients seriously ill, on efavirenz-based ART, had ART changed or interrupted for more than one month continuously any time during the preceding 18 months or on the second-line ART were not included in this study.

The Institutional Ethics committee of the National Institute for Research in Tuberculosis, Chennai, approved this study. Before enrolling into the study, informed written consent was obtained from all patients.

 {#sec2-1}

### Study procedures {#sec3-1}

A detailed clinical, socio-demographic and personal history, including smoking and alcohol intake, was collected using a structured questionnaire. Details on drug adherence over the last one year was retrieved from patient\'s ART notebooks that had information on number of pills supplied, number of pills returned and number of missed doses and by a basic five-point Likert scale for self-rating of overall adherence as all the time (excellent), most of the time (very good), many times (good), occasionally (fair) and never.

Height, weight, mid-arm, waist and hip circumferences were measured. Blood pressure was recorded in the left arm in sitting posture. After an overnight fast, blood samples (10 ml) were collected for lipid profile which included TC, HDL-C, LDL-C, TG and blood glucose, measured by an automated analyzer (Olympus AU400, Japan). A 10-yr risk for coronary heart disease was estimated using the Framingham\'s Point scores[@ref24]. Plasma samples were also subjected to viral load assay by Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0 (USA) and CD4 cell counts by FACSCount flow cytometer (Becton Dickinson, USA). Participants were genotyped for the polymorphisms in *APOC3* gene (rs2854116, rs2854117 and rs5128) by previously described primers using polymerase chain reaction (PCR) followed by sequencing assay[@ref14][@ref25]. The single nucleotide polymorphism (SNP) rs1800775 in *CETP* gene was determined by PCR and sequencing \[primers 5\'-AATGCCACAGACATTCCCCC-3\' (forward), 5\'-C GACCTTTCCCTTGCTCTGA-3\' (reverse)\] while *CETP* rs708272 (Taq1B) and *LPL* rs328 SNPs were analyzed by real-time PCR using TaqMan genotyping assay (Applied Biosystems, USA).

### Study definitions {#sec3-2}

For this study, hypertriglyceridaemia was defined as fasting TG \>150 mg/dl and hypercholesterolaemia as fasting cholesterol (TC) \>200 mg/dl or LDL-C \>130 mg/dl. HDL-C\< 40 mg/dl for males and \<50 mg/dl for females was defined as low HDL-C levels[@ref12]. Patients were classified as hypertensive or diabetics if they had been previously diagnosed with hypertension or diabetes or if they were on medical treatment for these disorders. A TC/HDL ratio of 4.5 or below for men and 4.0 or below for women was considered acceptable. Body mass index (BMI) of \>23 kg/m[@ref2] and waist circumference of \>90 cm for men and \>80 cm for women were considered as cut-offs for overweight and abdominal obesity, respectively, in this study[@ref26]. After one year of ART, plasma viral load of \<400 copies/ml was considered as virological suppression. Viral load between 400 and 1000 copies/ml was taken as blips while viral load \>1000 copies/ml after one-year of ART was taken as virological failure.

### Statistical analysis {#sec3-3}

Our previous study showed HDL-C levels below the lower limit of normal in about 25 per cent of HIV-infected Indians while on NNRTI-based ART[@ref23]. Based on this, it was planned to enrol 300 HIV-infected patients after one year of ART, to determine the association between HDL-C levels, gene polymorphisms and other risk factors.

SPSS software version 19.0 (IBM Corp, Armonk, NY, USA) was used to perform the data analysis. The data set was checked for logical inconsistencies and omissions. All unusual values were verified; normal distribution was checked. The outcomes of interest included the lipid parameters: TC, LDL-C, HDL-C, TG and TC/HDL-C ratio. Summary statistics is presented as proportions for categorical variables and as mean with standard deviation (SD) for continuous variables. A univariate regression followed by binary logistic regression by stepwise method was constructed to look for factors independently associated with abnormal lipid profile. Adjusted odds ratio (aOR) with its 95 per cent confidence intervals (CIs) was obtained. Candidate SNPs were evaluated in a logistic regression model and mean lipid levels compared between the different allele groups using Tukey analysis of variance at 5 per cent level. Pearson\'s Chi-square statistics was used to compare the proportions of patients with abnormal lipid values.

Results {#sec1-2}
=======

During the study period, 355 HIV-infected adults on NVP-based first-line ART for the past 12-15 months were screened for participation. Of them, 300 patients consented to participate in the study. Their mean age was 38.6±8.7 yr (range: 20-60 yr), mean CD4 cell count was 449±210 cell/μl and median duration of ART was 13.5 months (12-15 months); 26 per cent of the study participants were smokers; 53 per cent (159) were females ([Table I](#T1){ref-type="table"}). Eighty four per cent (252) had zidovudine, 8 per cent stavudine and another 8 per cent tenofovir as one of the nucleoside reverse transcriptase inhibitors in the regimen, along with lamivudine and NVP. The current National ART programme in India[@ref27] considers an optimum ART adherence level of ≥95 per cent. After one year of ART, overall adherence (based on the Likert scale of self-rating adherence) of \>95 per cent was found in 72 per cent (n=216) of study participants. Another 22 per cent (n=65) were 80-95 per cent adherent to drugs. Virological suppression of \<400 copies/ml was present in 89 per cent (n=268) of the patients. Three patients had viral load between 400 and 1000 copies/ml while 29 had viral load \>1000 copies/ml after one year of ART.

###### 

Demographic and clinical characteristics of the study participants on antiretroviral therapy (n=300)

![](IJMR-145-641-g001)
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### Lipid profile of participants {#sec3-4}

The mean serum TC was 189±45.6 mg/dl with hypercholesterolaemia in 116 (39%) patients ([Figure](#F1){ref-type="fig"}). Thirty per cent of them had LDL-C of \>150 mg/dl and the mean LDL-C was 111.3±36.3 mg/dl. Hypertriglyceridaemia was seen in 93 patients (31%) with mean TG level of 240.3±118.9 mg/dl. Forty one of 141 males (29%) had HDL-C \<40 mg/dl while 75 of 159 females (47%) had HDL-C \<50 mg/dl; 32 per cent of males and 37 per cent of females had TC/HDL-C ratio greater than the reference value of 4.5 and 4.0, respectively.

![Prevalence of dyslipidaemia in HIV-infected patients on antiretroviral therapy. Abnormal cholesterol=Fasting cholesterol 200 mg/dl; Abnormal triglycerides (TG)=Fasting triglycerides \>150 mg/dl. Abnormal high-density lipoprotein-cholesterol (HDL-C)= \<40 mg/dl for male, \<50 mg/dl for females; Abnormal Low-density lipoprotein-cholesterol (LDL-C) = \>130 mg/dl and Abnormal total cholesterol (TC): HDL-C ratio = \>4.5.](IJMR-145-641-g002){#F1}

### Factors associated with poor lipid profiles {#sec3-5}

In univariate analysis, weight \>55 kg (OR=1.96, 95% CI: 1.23-3.14, P=0.005), waist circumference of \>75 cm (OR=2.20, 95% CI: 1.32-3.66, P=0.002) and hip circumference \>80 cm (OR=2.28, 95% CI: 1.16-4.47, P=0.017) and a detectable viral load were associated with TC level above the upper limit of normal ([Table II](#T2){ref-type="table"}). Similarly, weight \>55 kg (OR=2.08, 95% CI: 1.26-3.41, P=0.004), mid-arm circumference \>25 cm (OR=1.91, 95% CI: 1.09-3.35, P=0.025), waist circumference \>75 cm (OR=3.21, 95% CI: 1.79-5.74, P=0.001) and waist:hip ratio \>0.9 were associated with higher TG levels. BMI \>23 kg/m[@ref2] appeared to be associated with a poorer lipid profile in terms of high TC, LDL-C, TG and higher TC/HDL-C ratio ([Table II](#T2){ref-type="table"}). Detectable viral load \>400 copies/ml (OR=3.07, 95% CI: 1.45-6.52, P=0.002) while on treatment was significantly associated with higher odds of having abnormal HDL-C at end of one-year of ART. Alcohol consumption, higher BMI and waist circumference \>75 cm were also associated with abnormal HDL-C after a year of ART though these did not reach significance. Men had a lower risk of having low HDL-C as compared to women in the similar age (OR=0.45, 95% CI 0.28-0.73, P=0.001) ([Table II](#T2){ref-type="table"}).

###### 

Association of lipid profile and various factors in our study participants (n=300)

![](IJMR-145-641-g003)

Considering gender, age, body weight, BMI, smoking status, alcohol use, waist and hip circumferences, CD4 cell count and viral load, using binary logistic regression by stepwise method, only BMI \>23 kg/m[@ref2] had an independent and positive association with all abnormal serum lipid levels -- TC \>200 mg/dl \[aOR (adjusted OR)=2.84, 95% CI: 1.76-4.60, P\<0.001); LDL-C \>130 mg/dl (aOR=1.83, 95% CI: 1.10-3.01, P=0.02\], TGL \>130 mg/dl (aOR=2.42, 95% CI: 1.37-4.28, P=0.002) and abnormal HDL-C (aOR=1.70, 95% CI: 1.02-2.84, P=0.04). High waist circumference had a positive association with TGL levels alone (aOR=2.13, 95% CI: 1.11-4.07, P\<0.01), while detectable viral load was negatively associated with serum HDL-C levels (aOR=3.39, 95% CI: 1.53-7.52, P=0.003). Male gender was protective against low HDL-C in our study group (aOR 0.46, 95% CI: 0.28-0.78, P=0.003) (data not shown).

### Framingham\'s cardiovascular risk score {#sec3-6}

The 10-yr risk of coronary heart disease was estimated using the Framingham\'s point score and 97 per cent (n=289) of patients had a risk of \<10 per cent while 3 per cent of patients had 11-20 per cent risk of developing CVD at the end of one-year of ART.

### Effect of single nucleotide polymorphisms (SNP) in various genes {#sec3-7}

[Apolipoprotein C3 (*APOC3*) gene polymorphisms]{.ul}

Homozygous carriers of C allele in rs2854116 and rs5128 displayed a trend towards higher lipid levels after 12 months of ART, when compared to heterozygous or non-carriers; in fact, the non-carriers of this allele had the lowest lipid levels among the three groups ([Table IIIA](#T3A){ref-type="table"}). However, this difference was not significant. Further, among individuals with abnormal lipid profiles, there was no significant difference in the allelic frequencies of *APOC3* related rs2854116, rs2854117 and rs5128 polymorphism ([Table IIIA](#T3A){ref-type="table"}).

###### 

Lipid parameters between the genotype variants of apolipoprotein C3 related polymorphisms among 295 study participants

![](IJMR-145-641-g004)

[Cholesteryl ester transfer protein (*CETP*)-related polymorphisms]{.ul}

Homozygous carriers of A allele in rs708272 of *CETP* showed a trend towards a higher HDL-C as compared with subjects with GG genotype in both genders ([Table IIIB](#T3B){ref-type="table"}). However, this difference was not significant.

###### 

Association between cholesteryl ester transfer protein (*CETP*) polymorphism and serum high-density lipoprotein cholesterol (HDL-C) levels
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[Lipoprotein lipase (*LPL*)-related polymorphisms]{.ul}

Proportion of various polymorphism of *LPL* gene in the low-, middle-, and upper-decile HDL-C levels did not show any significance in any particular group though a trend was seen in patients with homozygous carriers of C allele toward a low HDL-C ([Table IIIC](#T3C){ref-type="table"}).

###### 

Association between lipoprotein lipase (*LPL*) polymorphism and serum high-density lipoprotein (HDL) cholesterol levels

![](IJMR-145-641-g006)

Only the heterozygous carriers of C allele in *APOC3* rs2854117 (aOR1.45, 95% CI 0.99-3.09, P= 0.05) seemed to have a protective effect against abnormal HDL-C. None of the other SNPs of *APOC3*, *CETP* or *LPL* genes had any significant association with abnormal HDL-C ([Table IV](#T4){ref-type="table"}). In our study, 29 patients had detectable viral load and their drug adherence was \<80 per cent. The analysis was repeated after excluding these 29 patients with virological failure, but no significant association was found with either *APOC3*, *CETP* or *LPL* gene polymorphisms or low HDL-C.

###### 

Association of genetic variants in genes associated with high-density lipoprotein (HDL)-cholesterol
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Discussion {#sec1-3}
==========

Our study revealed low HDL-C levels in 39 per cent HIV-infected patients receiving NVP-based first-line ART. Higher BMI and unsuppressed viral load were significantly associated with low levels of HDL-C after 12 months of NVP-based first-line ART. Hypercholesterolaemia (39%), raised levels of LDL-C (30%) and hypertriglyceridaemia (31%) were the other forms of dyslipidaemia seen.

Though high, occurrence of HDL-C levels below the reference value after one year of ART was much lower to the reported rate of 50.8 per cent in patients using HAART for at least six months in Ethiopia[@ref3]. However, this was higher than that observed in a clinical trial cohort from the same setting as well as other studies from developing world[@ref17][@ref22][@ref23][@ref28]. Our patients were predominantly from a lower socio-economic background and from semi-urban setting and did not have high rates of obesity.

Multiple factors contribute to dyslipidaemia in HIV-infected individuals including HIV virus itself, chronic inflammation, individual genetic characteristics and ART-induced metabolic changes[@ref29]. Higher BMI and waist circumference were associated with hypercholesterolaemia, hypertriglyceridaemia and low HDL-C levels emphasizing the potential role of lifestyle (diet and exercise) in this population. Lifestyle changes may be beneficial and can be recommended for patients on ART. Furthermore, suppressed viral load was a protective factor against low HDL-C levels. This negative association between viral load and HDL-C levels observed in our study has also been noticed in other studies, even in ART-naïve individuals, indicating the role of HIV infection *per se* casuing low HDL-C levels[@ref22][@ref30][@ref31]. Hence, detectable viral load along with low HDL-C, in HIV-infected individual, after one year of stable ART, should raise the suspicion of non-adherence to ART even though the self-reporting indicates \>95 per cent adherence.

A small number of patients in our study (n=8) had a 11-20 per cent 10-yr risk of developing coronary heart disease and all of them had low levels of HDL-C. Although this was a small number, all efforts should be made to normalize their HDL-C levels as for every one per cent increase in HDL-C, there is a three per cent reduction in death or myocardial infarction[@ref10]. A study from north India has shown a greater prevalence of polymorphism in *APOC3* promoter region (C-482T and T-455C) among non-HIV subjects with metabolic syndrome and dyslipidaemia as compared to controls (frequency of 71 and 82% vs. 43 and 54%, P=0.0001)[@ref13]. However, we were not able to identify significant associations between the *APOC3*-related polymorphism and lipid parameters in our study. Homozygous carriers of C allele in rs5128 showed a trend towards more individuals with normal HDL-C levels when compared to heterozygous or non-carriers. Similar results have also been reported by a Spanish group where A allelic variant of the rs10892151 polymorphism was not found to be associated with serum *APOC3* concentration but predisposes HIV-infected patients to less favourable lipid profile[@ref32]. Considering the crucial role of *CETP* and *LPL* genes in lipid metabolism, the association of SNPs of these genes with low HDL-C levels was examined but no significant association between low HDL-C and gene polymorphisms was observed. A few other studies have shown an association between *CETP* and lipid metabolism[@ref16][@ref33][@ref34]. The reports from India are varied as each has looked at different *CETP* polymorphisms and HDL-C metabolism[@ref35][@ref36]. In the study by Dixit *et al*[@ref36], lipid profile analysis did not show any significant difference in distribution among genotypes of *CETP* polymorphism among patients and controls. These contradictory results in different populations indicate that various mutation/polymorphisms of *APOC3* and *CETP* are involved with HDL-C metabolism and more research is needed in this field.

A cross-sectional study design and a lack of control group were major limitations in this study. As we did not have baseline data on these individuals or a control group with similar baseline characters but without these changes at one year, we could not examine changes induced by ART use and what the baseline prevalence of dyslipidaemia was. No data were collected on dietary and other lifestyle factors that might have an impact on lipid profiles. The sample size was adequate for the lipid analysis, with a power \>90 per cent, but may have been small to detect differences in gene polymorphisms.

In conclusion, our results indicated that a high proportion of HIV-infected patients had a low HDL-C level after one year of NVP-based ART. Association was found between NVP-based ART and high-risk lipid profiles for atherosclerosis and CVD raising concerns about their long-term morbidity. Targeted interventions such as periodic monitoring of lipid levels, dietary modification, physical exercise and good virological control need be recommended as part of the national ART programmes.
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